Thermo Fisher Scientific | TMO - Current Liabilities


Thermo Fisher Scientific reported $14.62B in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Abbott USD 18.38B 1.88B Mar/2026
Agilent USD 2.27B 35M Mar/2026
Becton, Dickinson and Co. USD 8.51B 254M Mar/2026
Bio Techne USD 153.28M 12.85M Mar/2026
Bio-Rad Laboratories USD 917M 400M Mar/2026
Boston Scientific USD 4.57B 868M Mar/2026
Bruker USD 1.36B 75.9M Mar/2026
Charles River Laboratories USD 1.09B 26.61M Mar/2026
Danaher USD 7.46B 653M Mar/2026
Dentsply International USD 1.21B 136M Mar/2026
Edwards Lifesciences USD 1.41B 404.7M Mar/2026
General Electric Aerospace USD 40.03B 1.05B Mar/2026
Henry Schein USD 3.3B 69M Mar/2026
Illumina USD 1.57B 19M Mar/2026
Intuitive Surgical USD 2.51B 3.2M Mar/2026
IQVIA Holdings USD 8.33B 9M Mar/2026
Laboratory Of America USD 2.64B 182.5M Mar/2026
Medtronic USD 9.5B 440M Dec/2025
Mettler Toledo International USD 1.11B 89.76M Mar/2026
Myriad Genetics USD 130.2M 3.6M Mar/2026
Olympus JPY 436.87B 36.14B Mar/2026
OraSure Technologies USD 44.08M 4.29M Mar/2026
Quest Diagnostics USD 2.18B 101M Mar/2026
Repligen USD 126.21M 9.62M Mar/2026
Revvity USD 1.24B 92.6M Mar/2026
Stryker USD 6.32B 1.48B Mar/2026
Thermo Fisher Scientific USD 14.62B 568M Mar/2026
Veracyte USD 56.11M 3.82M Mar/2026
Waters USD 1.24B 11.8M Dec/2025
Zimmer Biomet Holdings USD 2.86B 280.6M Mar/2026